| 1429 |
National Cancer Institute |
Html |
en |
Neuroblastoma Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for neuroblastoma. |
| cancer treatment | 0.486632 |
| cancer screening methods | 0.582299 |
| ongoing clinical trials | 0.502871 |
| neuroblastoma | 0.698844 |
| PDQ cancer information | 0.80843 |
| false-negative test result | 0.502128 |
| NCI Web site | 0.507263 |
| clinical trials | 0.709878 |
| vanillyl mandelic acid | 0.576656 |
| test result | 0.623055 |
| nerve tissue | 0.489507 |
| cancer information summary | 0.657568 |
| clinical trial | 0.522829 |
| breast cancer prevention | 0.512391 |
| diagnostic tests | 0.506931 |
| test results | 0.491146 |
| false-positive test result | 0.501632 |
| PDQ summaries | 0.524226 |
| latest published information | 0.506403 |
| PDQ® Screening | 0.491512 |
| NCI’s PDQ | 0.527909 |
| cancer symptoms | 0.501892 |
| NCI PDQ cancer | 0.598105 |
| PDQ Neuroblastoma Screening | 0.65982 |
|
| tests | 0.548148 |
| routine screening test | 0.556554 |
| Neuroblastoma Treatment | 0.531296 |
| new cases | 0.489109 |
| PDQ Screening | 0.567089 |
| screening tests | 0.516882 |
| homovanillic acid | 0.494688 |
| Cancer Information Service | 0.531924 |
| urine test result | 0.504837 |
| Prevention Editorial Board | 0.562279 |
| treatment clinical trials | 0.501764 |
| National Cancer Institute | 0.643496 |
| PDQ documents | 0.515811 |
| new treatment | 0.51605 |
| health professional version | 0.484258 |
| Cancer screening trials | 0.58895 |
| PDQ database | 0.522175 |
| Cancer Care page | 0.516301 |
| adrenal glands | 0.539844 |
| PDQ summary | 0.591543 |
| cancer information summaries | 0.540208 |
| health professional versions | 0.487782 |
| comprehensive cancer information | 0.541053 |
| cancer | 0.90999 |
|
CLICK HERE |
| 1671 |
National Cancer Institute |
Html |
en |
Oral Cavity and Oropharyngeal Cancer Prevention (PDQ®)–Patient Version |
Expert-reviewed information summary about factors that may influence the risk of developing cancer of the lip or mouth and about approaches that may help in the prevention of this disease. |
| cancer risk factors | 0.223252 |
| Cancer prevention | 0.365011 |
| cancer prevention trials | 0.261397 |
| cancer protective factor | 0.204761 |
| prevention clinical trials | 0.211212 |
| oropharyngeal cancers | 0.216475 |
| oral HPV infection | 0.208202 |
| protective factors | 0.215254 |
| oral HPV | 0.208586 |
| following PDQ summaries | 0.206276 |
| oropharyngeal cancer prevention | 0.350667 |
| PDQ cancer information | 0.33357 |
| cavity cancer forms | 0.258314 |
| oral cavity cancer | 0.981873 |
| Oropharyngeal cancer forms | 0.281694 |
|
| alcoholic drinks | 0.202431 |
| Prevention Editorial Board | 0.202298 |
| National Cancer Institute | 0.263899 |
| clinical trials | 0.351443 |
| oral cancer | 0.226352 |
| cancer information summary | 0.25617 |
| PDQ Oral Cavity | 0.273609 |
| oropharyngeal cancer increases | 0.352455 |
| cancer risk factor | 0.224482 |
| NCI PDQ cancer | 0.229249 |
| cavity cancer prevention | 0.250253 |
| cancer clinical trials | 0.204322 |
| risk factors | 0.306174 |
| cancer information summaries | 0.200668 |
| comprehensive cancer information | 0.201344 |
|
CLICK HERE |
| 1749 |
National Cancer Institute |
Html |
en |
Helicobacter pylori and Cancer |
A fact sheet about the relationship between H. pylori infection and gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, and other cancers. |
| gastric malt lymphoma | 0.326658 |
| M. Gastric cancer | 0.212884 |
| H. pylori | 0.843788 |
| H. pylori colonization | 0.258268 |
| gastric cancer rates | 0.221795 |
| cagA-negative H. pylori | 0.255803 |
| Helicobacter pylori infection | 0.310803 |
| gastric adenocarcinoma | 0.207225 |
| Helicobacter pylori | 0.602968 |
| F. Helicobacter pylori | 0.25223 |
| noncardia gastric cancer | 0.213325 |
| non-cardia gastric cancer | 0.587912 |
|
| H. pylori infection | 0.660511 |
| caga-positive h. pylori | 0.364356 |
| gastric cancer | 0.957743 |
| M. Helicobacter pylori | 0.251667 |
| Helicobacter pylori CagA | 0.252645 |
| Helicobacter pylori seropositivity | 0.402047 |
| gastric cancer incidence | 0.328991 |
| Overall gastric cancer | 0.233481 |
| esophageal adenocarcinoma | 0.208828 |
| et al | 0.379167 |
| pylori infection rates | 0.297929 |
| gastric cardia cancer | 0.470154 |
|
CLICK HERE |
| 1932 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) masculino (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama) masculino. |
| proteÃna tipo factor | 0.688463 |
| siguientes procedimientos | 0.676775 |
| ensayo clÃnico quizás | 0.629367 |
| masculino causa efectos | 0.681409 |
| estadio iv | 0.660278 |
| siguientes aspectos | 0.673259 |
| causa hinchazón | 0.616649 |
| pared torácica).ampliar mastectomÃa | 0.62845 |
| siguientes tipos | 0.637367 |
| estadios ia | 0.617736 |
| ganglio linfático centinela | 0.976846 |
| metastásico recién | 0.62148 |
| rayos x | 0.618438 |
| estadio ib | 0.633026 |
| enlace drugs approved | 0.678672 |
| estadio ia | 0.632429 |
| parientes mujeres | 0.619901 |
| CaracterÃsticas genéticas | 0.619237 |
| National Cancer Institute | 0.617425 |
| siguientes riesgos | 0.617906 |
| nota cambios | 0.619802 |
| Instituto Nacional | 0.630039 |
|
| cuáles lesiones | 0.617135 |
| PDQ Tratamiento | 0.673691 |
| antecedentes familiares | 0.667022 |
| estadio iiic | 0.707564 |
| estadio iiib | 0.663127 |
| Drugs Approved | 0.68451 |
| partes distantes | 0.61448 |
| Physician Data Query | 0.660883 |
| siguientes sitios | 0.627559 |
| Breast Cancer | 0.680102 |
| siguientes caracterÃsticas | 0.628479 |
| siguientes terapias | 0.621354 |
| quede.ampliar cirugÃa | 0.621258 |
| cuerpo llamada ecograma | 0.655581 |
| Carcinoma lobulillar | 0.625171 |
| tipo estadio iiib | 0.641656 |
| especial parientes | 0.620527 |
| crecimiento her2 | 0.616687 |
| cáncer quizás | 0.765886 |
| genes brca1 | 0.623395 |
| siguientes pruebas | 0.678579 |
| siguientes sumarios | 0.647742 |
|
CLICK HERE |
| 1968 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer escamoso metastásico de cuello con tumor primario oculto. |
| PDQ Tratamiento | 0.637237 |
| glándula tiroides | 0.630286 |
| tratamiento.Ciertas formas | 0.62926 |
| siguientes procedimientos | 0.80319 |
| alta potencia | 0.638988 |
| presente sección | 0.626186 |
| Physician Data Query | 0.682277 |
| rayos x | 0.641083 |
| pequeñas marcas | 0.628464 |
|
| cáncer.ampliar radioterapia | 0.682908 |
| siguientes enlaces | 0.620289 |
| vÃas respiratorias | 0.946667 |
| National Cancer Institute | 0.61827 |
| siguientes riesgos | 0.612805 |
| siguientes pruebas | 0.658061 |
| Instituto Nacional | 0.682711 |
| hormonas tiroideas | 0.630783 |
| malla ayuda | 0.628658 |
|
CLICK HERE |
| 1974 |
National Cancer Institute |
Html |
es |
Tratamiento del melanoma ocular uveal (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del melanoma ocular uveal. |
| radiocirugÃa estereotáctica | 0.330709 |
| ocular uveal causa | 0.426278 |
| siguientes procedimientos | 0.458381 |
| siguientes aspectos | 0.383299 |
| pequeña cantidad | 0.327431 |
| mejores opciones | 0.35302 |
| siguientes tipos | 0.347433 |
| rayos x | 0.408559 |
| rayos gamma | 0.32586 |
| ondas sonoras | 0.908476 |
| alta resolución | 0.353742 |
| tumor pequeño decrecimiento | 0.686457 |
| siguientes riesgos | 0.308525 |
| Gamma Knife | 0.437319 |
|
| grueso.ampliar milÃmetros | 0.513411 |
| Instituto Nacional | 0.321875 |
| estadio iiia | 0.453733 |
| PDQ Tratamiento | 0.318045 |
| partÃculas minúsculas | 0.329297 |
| estadio iiic | 0.36212 |
| estadio iia | 0.724706 |
| siguientes signos | 0.397324 |
| Physician Data Query | 0.349033 |
| lápiz mide | 0.428384 |
| placa ayuda | 0.329458 |
| capa coroidea | 0.363432 |
| siguientes pruebas | 0.476577 |
|
CLICK HERE |
| 3458 |
National Cancer Institute |
Html |
es |
Aromaterapia y aceites esenciales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del uso de la aromaterapia y los aceites esenciales para mejorar la calidad de vida de los pacientes de cáncer. |
| QueaseEaseâ„¢ essential oil | 0.322888 |
| Palliat Nurs | 0.354113 |
| with dementia | 0.319927 |
| Using aromatherapy | 0.319114 |
| Adv Nurs | 0.330674 |
| aromatherapy massage benefit | 0.323369 |
| aromatherapy massage | 0.460246 |
| aceite portador | 0.411771 |
| effects upon inhalation | 0.330851 |
| with sedative effects | 0.339649 |
| Essential oils as | 0.328315 |
| essential oils with | 0.364947 |
| sedative effects upon | 0.328613 |
| Estados Unidos | 0.358013 |
| Wilkinson S | 0.324749 |
| Complement Ther Nurs | 0.326064 |
| Ther Nurs Midwifery | 0.325274 |
| An evaluation | 0.330236 |
| essential oil against | 0.321713 |
| Inhalation aromatherapy during | 0.319826 |
| patients with | 0.403468 |
| essential oil from | 0.322691 |
| lavandula vera dc | 0.321359 |
| randomized controlled | 0.329336 |
| essential oils | 0.975981 |
|
| malignant brain tumours | 0.320542 |
| Altern Complement Med | 0.328888 |
| wound care | 0.337271 |
| células madre | 0.337232 |
| contact dermatitis from | 0.318516 |
| Essential Oil Therapeutics | 0.348142 |
| frecuencia escogen aceites | 0.330608 |
| palliative care | 0.34198 |
| using essential oils | 0.330409 |
| Antibacterial essential oils | 0.327832 |
| New York | 0.317733 |
| Fragrance compounds | 0.318588 |
| Lavandula angustifolia | 0.324093 |
| Palliat Med | 0.41168 |
| Inhalation aromatherapy | 0.326733 |
| verdaderos aceites | 0.357046 |
| Van Toller S | 0.322917 |
| lavandula angustifolia miller | 0.322367 |
| Reino Unido | 0.345706 |
| from essential oils | 0.326193 |
| Aromatherapy as | 0.327736 |
| Essential Oil Blends | 0.324181 |
| oils with sedative | 0.344081 |
| Dodd GH | 0.321815 |
|
CLICK HERE |
| 3579 |
National Cancer Institute |
Html |
en |
Cancer Health Disparities Research |
NCI is addressing cancer health disparities through its efforts in basic research, community-level programs, and more. |
| cancer treatment | 0.363689 |
| cancer control continuum—from | 0.369693 |
| health care disparities | 0.45285 |
| American Cancer Society | 0.373854 |
| Breast Cancer Genetic | 0.374611 |
| NCI research programs | 0.364956 |
| cancer health disparities—such | 0.406746 |
| colorectal cancer | 0.373832 |
| American Breast Cancer | 0.39202 |
| Colorectal Cancer Outreach | 0.36747 |
| public health officials | 0.365199 |
| breast cancer outcome | 0.373209 |
| clinical cancer research | 0.388692 |
| Reduce Cancer Health | 0.386549 |
| health care facilities | 0.400047 |
| Breast Cancer Consortium | 0.371087 |
| population groups | 0.362749 |
| African American Breast | 0.367467 |
| care delivery research | 0.356797 |
| public health communities | 0.394704 |
| cancer health disparities | 0.942995 |
| NCI-Designated Cancer Centers. | 0.367758 |
| Documented cancer health | 0.404937 |
| certain racial/ethnic populations | 0.356837 |
| cancer research community | 0.391405 |
|
| Cancer Health Equity | 0.385722 |
| cancer research continuum | 0.381244 |
| cancer prevention | 0.353808 |
| prostate cancer deaths | 0.379501 |
| health disparities research | 0.467802 |
| cancer research | 0.471213 |
| African American men | 0.354676 |
| cancer screenings | 0.355012 |
| cancer screening rates | 0.368257 |
| cancer care—from access | 0.379244 |
| Breast Cancer Epidemiology | 0.371467 |
| African American women | 0.401312 |
| complex health care | 0.371446 |
| advanced cancer diagnoses—in | 0.382581 |
| community health educators | 0.353702 |
| breast cancer | 0.431984 |
| cancer care delivery | 0.39176 |
| cancer disparities | 0.490093 |
| NCORP cancer care | 0.377954 |
| experience cancer-related health | 0.363186 |
| cancer clinical trials | 0.389742 |
| cancer risk | 0.352747 |
| cancer death rates | 0.384903 |
| cancer incidence | 0.357189 |
|
CLICK HERE |
| 3885 |
National Cancer Institute |
Html |
en |
Recurrent Cancer: When Cancer Comes Back |
Cancer can recur when treatment doesn’t fully remove or destroy all the cancer cells. Learn about the different types of recurrence and how recurrent cancer is restaged and treated. |
| childhood cancers | 0.476868 |
| Distant recurrence | 0.50571 |
| original cancer | 0.564629 |
| sadness | 0.421168 |
| metastatic cancer | 0.487966 |
| type | 0.513612 |
| follow-up tests | 0.479719 |
| body | 0.434324 |
| anger | 0.419198 |
| treatments | 0.459728 |
| new stage | 0.530501 |
| new type | 0.47242 |
| before—experience | 0.42036 |
| fear | 0.418153 |
| distant place | 0.475453 |
| tissues | 0.43928 |
| shock | 0.418728 |
| diagnosis | 0.431005 |
| imaging procedures | 0.478142 |
| history | 0.416978 |
| recurrence | 0.563784 |
| different types | 0.481078 |
| recurrent cancer | 0.74671 |
| effects | 0.417676 |
| tests | 0.513085 |
|
| PDQ® cancer treatment | 0.538695 |
| lymph nodes | 0.48537 |
| New drugs | 0.480401 |
| chronic disease | 0.48607 |
| doctors | 0.43873 |
| new assessment | 0.472279 |
| treatment | 0.554752 |
| primary cancer | 0.524976 |
| Local recurrence | 0.508295 |
| methods | 0.41771 |
| cancer cells | 0.53799 |
| lab tests | 0.472499 |
| metastasis | 0.419606 |
| Regional recurrence | 0.507489 |
| cases | 0.417606 |
| colon cancer | 0.521555 |
| original stage | 0.470341 |
| people | 0.436769 |
| doctor | 0.449906 |
| tumors | 0.41688 |
| cancer | 0.972673 |
| new cancer | 0.482803 |
| time | 0.417134 |
| small number | 0.481583 |
|
CLICK HERE |
| 16795 |
National Cancer Institute |
Html |
en |
2015 Outstanding Investigator Award Recipients |
Learn how these investigators' projects aim to break new ground in biomedical, behavioral, and clinical cancer research. |
| Professor | 0.738812 |
| Family Comprehensive Cancer | 0.697633 |
| Nutrition Research Institute | 0.632397 |
| Cancer Society Professor | 0.656988 |
| Southwestern Medical Center | 0.618128 |
| Institution | 0.848522 |
| research | 0.851243 |
| cancer therapy | 0.619746 |
| cancer stem cell | 0.628165 |
| Helen Diller Family | 0.632348 |
| Harvard Medical School | 0.794066 |
| Wilmot Cancer Institute | 0.62515 |
| Cancer Center | 0.910562 |
| cancer prevention strategies | 0.633636 |
| end-of-life cancer care | 0.629483 |
| Masonic Cancer Center | 0.656865 |
| ovarian cancer | 0.628349 |
| p53 suppresses cancer | 0.650445 |
| University Medical Center | 0.724171 |
| PhD | 0.753295 |
| human cancer | 0.640527 |
| ovarian cancer genes | 0.61365 |
| Scripps Research Institute | 0.619487 |
| cancer therapeutic modality | 0.630386 |
| breast cancer cells | 0.62334 |
|
| population sciences research | 0.61394 |
| Lineberger Comprehensive Cancer | 0.676511 |
| cancer cells | 0.654777 |
| Cancer Research Institute | 0.686442 |
| Environmental Health Research | 0.629607 |
| Medical Center | 0.756685 |
| Dana-Farber Cancer Institute | 0.788794 |
| pancreatic cancer | 0.625795 |
| acute myeloid leukemia | 0.637274 |
| cancer stem cells | 0.621012 |
| MD Anderson Cancer | 0.64898 |
| Lombardi Comprehensive Cancer | 0.617543 |
| Brain Tumor Center | 0.624289 |
| Title | 0.775608 |
| breast cancer | 0.628242 |
| Comprehensive Cancer Center | 0.859355 |
| medicine | 0.614674 |
| Deaconess Medical Center | 0.617175 |
| new research frameworks | 0.62712 |
| University Feinberg School | 0.730895 |
| new cancer therapies | 0.626793 |
| Lerner Research Institute | 0.616532 |
| tumor | 0.643642 |
| cancer cell homeostasis | 0.635237 |
|
CLICK HERE |